Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 4 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

Clinical Trial of TB511 in Advanced Solid TumorsNot yet recruitingNCT06400160Phase 1/2 Report a problem
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)RecruitingNCT06393374Phase 3 Report a problem
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck CancerRecruitingNCT06385080Phase 1/2 Report a problem
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid TumorsRecruitingNCT06384352Phase 1 Report a problem
A Study of BV-AVD in People With Bulky Hodgkin LymphomaRecruitingNCT06377566Phase 2 Report a problem
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With PembrolizumabNot yet recruitingNCT06371807Phase 2 Report a problem
ALPINE: Maintenance Letrozole/AbemaciclibRecruitingNCT06366347Phase 2 Report a problem
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKKRecruitingNCT06358573Phase 2 Report a problem
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC PatientsRecruitingNCT06353997Phase 2 Report a problem
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)RecruitingNCT06345729Phase 3 Report a problem
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerRecruitingNCT06343402Phase 1 Report a problem
Investigator Grant (IG) 2022 27746RecruitingNCT06341478Not applicable Report a problem
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric AdenocarcinomaRecruitingNCT06340711Phase 2 Report a problem
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerRecruitingNCT06324240Phase 1 Report a problem
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingNCT06312176Phase 3 Report a problem
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)RecruitingNCT06312137Phase 3 Report a problem
Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly PatientsRecruitingNCT06311981Phase 2 Report a problem
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)RecruitingNCT06295731Phase 2/3 Report a problem
Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06293651Phase 1/2 Report a problem
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma PatientsRecruitingNCT06284590Phase 2 Report a problem
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerRecruitingNCT06282575Phase 3 Report a problem
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsRecruitingNCT06270706Phase 1 Report a problem
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid TumorsRecruitingNCT06265025Phase 1/2 Report a problem
A Phase 1/1b Study of IAM1363 in HER2 CancersRecruitingNCT06253871Phase 1 Report a problem
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial CancerRecruitingNCT06253494Phase 1/2 Report a problem
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With PembrolizumabRecruitingNCT06249048Phase 1/2 Report a problem
A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast CancerRecruitingNCT06246968Phase 1 Report a problem
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCRecruitingNCT06245889Phase 2 Report a problem
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid TumorsRecruitingNCT06244771Phase 1/2 Report a problem
A Study of MGC026 in Participants With Advanced Solid TumorsRecruitingNCT06242470Phase 1 Report a problem
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid TumorsRecruitingNCT06234397Phase 1 Report a problem
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsRecruitingNCT06228326Phase 1/2 Report a problem
Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer PatientsRecruitingNCT06225284Phase 2 Report a problem
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCRecruitingNCT06216301Phase 3 Report a problem
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast CancerRecruitingNCT06197581Not applicable Report a problem
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RecruitingNCT06170788Phase 3 Report a problem
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingNCT06162221Phase 1/2 Report a problem
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell CarcinomaRecruitingNCT06161545Phase 2 Report a problem
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerRecruitingNCT06157151Phase 2 Report a problem
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2 Report a problem
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.RecruitingNCT06137144Phase 1/2 Report a problem
Metastasis-directed Therapy for Oligometastases of Breast CancerRecruitingNCT06135714Phase 3 Report a problem
A Study of Tetrathiomolybdate (TM) Plus CapecitabineRecruitingNCT06134375Phase 1/2 Report a problem
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Phase 3 Report a problem
Palbociclib and Pembrolizumab in SarcomaRecruitingNCT06113809Phase 1 Report a problem
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid TumorsRecruitingNCT06108050Phase 1 Report a problem
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialRecruitingNCT06096844Phase 3 Report a problem
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ AdenocarcinomaNot yet recruitingNCT06093425Phase 3 Report a problem
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus ChemotherapyRecruitingNCT06084897Phase 2 Report a problem
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid TumorsRecruitingNCT06063681Phase 1 Report a problem
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCCRecruitingNCT06052839Phase 2 Report a problem
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisRecruitingNCT06047379Phase 1/2 Report a problem
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung CancerNot yet recruitingNCT06045767Phase 2 Report a problem
Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly PatientsRecruitingNCT06032052Phase 2 Report a problem
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction ImmunochemotherapyNot yet recruitingNCT06031597Phase 3 Report a problem
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell CarcinomaRecruitingNCT06016920Phase 1/2 Report a problem
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid TumorsRecruitingNCT06004245Phase 1 Report a problem
The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung CancerRecruitingNCT06000358Not applicable Report a problem
Prediction in Silico of Pathological Response in a Prospective Cohort Study of Early Breast Cancer PatientsRecruitingNCT05981326Not applicable Report a problem
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid TumorsRecruitingNCT05978102Phase 1/2 Report a problem
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and SurgeryRecruitingNCT05973864Phase 2 Report a problem
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid TumorsRecruitingNCT05970497Phase 1/2 Report a problem
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309RecruitingNCT05957081Phase 1 Report a problem
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid TumorsRecruitingNCT05954312Phase 1 Report a problem
Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.RecruitingNCT05937906Phase 1/2 Report a problem
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerRecruitingNCT05929768Phase 3 Report a problem
Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic CancerRecruitingNCT05916261Early Phase 1 Report a problem
Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid TumorsRecruitingNCT05916248Early Phase 1 Report a problem
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid TumorsRecruitingNCT05907980Phase 1 Report a problem
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid TumorsRecruitingNCT05901285Phase 1 Report a problem
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung CancerRecruitingNCT05886439Phase 1/2 Report a problem
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic CancerRecruitingNCT05877430Phase 1/2 Report a problem
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)RecruitingNCT05872867Phase 1 Report a problem
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor CancerRecruitingNCT05859074Phase 1 Report a problem
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid TumorsRecruitingNCT05856981Phase 1 Report a problem
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)RecruitingNCT05849480Phase 1/2 Report a problem
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck CancerRecruitingNCT05838729Phase 1/2 Report a problem
Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint InhibitorsRecruitingNCT05834413Not applicable Report a problem
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)RecruitingNCT05824975Phase 1/2 Report a problem
The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint InhibitorsRecruitingNCT05821751Not applicable Report a problem
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck CancerRecruitingNCT05815927Phase 3 Report a problem
Grouping Immune-modulation With Cryoablation (LOGIC) for Breast CancersNot yet recruitingNCT05806385Phase 1/2 Report a problem
pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal CancerRecruitingNCT05799144Phase 2 Report a problem
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsRecruitingNCT05797168Phase 1/2 Report a problem
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationRecruitingNCT05789082Phase 1/2 Report a problem
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid TumorsRecruitingNCT05785754Phase 1 Report a problem
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid TumorsRecruitingNCT05784688Phase 1/2 Report a problem
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung CancerRecruitingNCT05777603Phase 1 Report a problem
Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 TrialRecruitingNCT05763992Phase 2 Report a problem
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849RecruitingNCT05761223Phase 1/2 Report a problem
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid TumorsRecruitingNCT05746897Phase 1 Report a problem
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLCRecruitingNCT05745350Phase 2 Report a problem
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast CancerRecruitingNCT05741164Phase 2 Report a problem
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)RecruitingNCT05733689Phase 1 Report a problem
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsRecruitingNCT05732831Phase 1/2 Report a problem
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.RecruitingNCT05727904Phase 3 Report a problem
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2 Report a problem
A Study of ASP1002 in Adults for Treatment of Solid TumorsRecruitingNCT05719558Phase 1 Report a problem
A Study of EBC-129 in Advanced Solid TumoursRecruitingNCT05701527Phase 1 Report a problem
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLCRecruitingNCT05669846Phase 2 Report a problem

← Pembrolizumab